Indeed, TIGIT inhibition significantly delayed tumor growth in HNSCC mouse models and enhanced antitumor immune responses by activating effector CD8+ T cells and reducing immunosuppressive cells, including Tregs and MDSCs [85]. The gene discussed is CD8A; the disease is head and neck squamous cell carcinoma.